TickerTalks
Browse all tickers →
TickerTalks›$NNOX
NNNNOX

Nano-X Imaging Ltd.

$NNOX·$74M·Medical - Devices·Healthcare
$1.00+1.3%YTD-62.8%1Y-77.8%
Mentions · last 7 days
2026-08-07: 3 posts2026-08-08: 1 posts2026-08-09: 0 posts2026-08-10: 8 posts2026-08-11: 4 posts2026-08-12: 1 posts2026-08-13: 2 posts19-48%
Price updated 1d ago·X counts updated 2d ago
NNNNOX
$NNOXNano-X Imaging Ltd.
$1.00+1.29%19 posts-48%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NNOX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storyWinding up for a moveAI verdict · as of 2026-08-14

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Nano-X Imaging down 78% in twelve months with a $8M dilutive ATM offering and active class actions — but 4 insider buys (3 distinct buyers in 30 days) give a rare cluster tell at the bottom.

Nano-X's four-quarter revenue is $3.0M → $3.4M → $3.7M → $4.3M with EPS -$0.20 to -$0.50 and gross margin deeply negative (installed-base build phase) — the underlying imaging-device business is scaling from a low base and burning cash to do it.

  • Insider signal is decision-relevant: 4 open-market buys across 3 distinct buyers in a 30-day window — Meltzer (officer + director) 9,443 shares at $1.03, Kainan (director) 33,000 shares at $0.90 — a rare cluster tell at a sub-$1 price during active class actions.
  • Consensus FY26 revenue $25.9M / EPS -$0.62, walking to $46.8M / -$0.38 FY27 and $87.3M / -$0.20 FY28 (2–3 analysts) — model implies revenue ramps ~2× per year through FY28, so the equity is priced on installed-base placement more than current P&L.
  • Multiple securities class actions active (Pomerantz, Bronstein, Portnoy, Faruqi) with a today-marked deadline; -78% over 12 months, position 6% of 52-week range, -22% below 50-day and -58% below 200-day MA — bombed-out base with the insider cluster at the low.

There's no next-earnings date in the bundle; the events are the $8M ATM completion, any additional insider Form 4s, class-action lead-plaintiff outcomes, and installed-base disclosure at investor conferences.

Agrees with X sentimentX reads the dilutive $8M raise cautiously while flagging the Teledyne/Varex $1.1B deal as a positive sector read-through and OpenVINO Intel integration as a real-tech positive — that mixed framing lines up with the setup: real product progress against a shaky capitalization.

What to watch: Completion of the $8M ATM offering, additional insider Form 4 filings, class-action lead-plaintiff outcomes, installed-base placement disclosure, and any partnering announcement.

On the calendar: Not disclosed — no scheduled earnings date in bundle

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment5 posts analyzed · as of 2026-08-13

Nano-X Imaging news is dominated by a dilutive $8M registered direct offering priced at-the-market, and users note the Teledyne/Varex Imaging $1.1B deal as a positive sector read-through. NNOX also touts optimizing its medical-imaging AI framework for Intel Core Ultra processors with OpenVINO. Tone is neutral to modestly bullish on the tech but wary on the raise.

Read the AI verdict + X sentiment for $NNOX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Medical device company developing an affordable MEMS-based digital X-ray system for point-of-care imaging and teleradiology AI diagnostics.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $NNOX.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

What this means for $NNOX

Partial — Medical device company developing an affordable MEMS-based digital X-ray system for point-of-care imaging and teleradiology AI diagnostics; partial earnings exposure to medical - devices demand dynamics through its product portfolio.

Industry benchmark

25-name peer basket
+10.5%YTD
+32.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-423%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-67.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-51.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-85.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Jun 25, 2026$-0.20$-0.14-42.9%
Q1 2026Apr 20, 2026$-0.50$-0.23-117.4%
Q3 2025Nov 20, 2025$-0.65$-0.15-333.3%
Q2 2025Aug 12, 2025$-0.23$-0.17-31.4%
Next earningsTue, Aug 18·consensus EPS $-0.16

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$4.3M+53.1%-62.6%-343%$-0.20$-15.7M
Q4 FY25$3.7M+24.0%-97.3%-481%$-0.50$-12.5M
Q3 FY25$3.4M+13.7%-83.6%-413%$-0.21$-12.5M
Q2 FY25$3.0M+12.6%-107%-477%$-0.23$-10.4M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$25.9M$22.1M – $29.9M-$0.62-$0.68 – -$0.543
FY27$46.8M$42.5M – $51.9M-$0.38-$0.46 – -$0.293
FY28$87.3M$84.4M – $90.1M-$0.20-$0.22 – -$0.172
FY29$140.9M$129.4M – $153.6M$0.08$0.07 – $0.091
FY30$192.5M$176.8M – $209.9M$0.33$0.30 – $0.371

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.6%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-22.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-57.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 64.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.275-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Cluster buy3 insiders bought shares in the last 30 days.

Recent transactions

BuyAug 10Erez MeltzerCEO9.4K sh$10KBuyJul 28Noga KainanDirector33.0K sh$30KBuyJul 27Dan S SuesskindDirector50.0K sh$47KBuyJul 27Erez MeltzerCEO36.0K sh$33KSellJun 10Erez AlroyDirector678 sh$1K
+ 2 other (2 returns) in window

See when $NNOX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 7424B5
AI summary

NNOX (NNOX) filed a prospectus supplement (Form 424B5) on 2026-08-07 for an immediate offering of shares $1.00 per share, raising approximately $1.00. . Use of proceeds: general corporate purposes. This is dilutive capital activity happening now, distinct from a shelf registration — new shares will be issued. Investors should assess pricing relative to market and stated use of proceeds to evaluate dilution impact.

3New insider — initial holdingsAug 33
AI summary

Guy Nathansohn, incoming Chief Financial Officer of Nano-X Imaging Ltd. (NNOX), filed an initial Form 3 reporting no securities beneficially owned as of August 1, 2026. Administrative filing required under Section 16(a) of the Securities Exchange Act of 1934 upon becoming an officer. No market-moving content.

424B5Prospectus supplement (offering)Jul 24424B5
AI summary

NNOX filed a 424B5 prospectus supplement under an at-the-market (ATM) equity offering facility, offering up to $54M. Shares will be sold from time to time through sales agents at prevailing market prices, with no single fixed deal price or settlement date. This represents ongoing dilutive equity issuance; current remaining capacity under the facility is $54M. ATM programs allow flexible, market-timed capital raises but represent incremental dilution to existing shareholders.

3New insider — initial holdingsApr 303
3New insider — initial holdingsApr 93
3New insider — initial holdingsApr 73
3New insider — initial holdingsApr 73
3New insider — initial holdingsMar 243
+ 23 other (7 6-Ks · 7 3s · 3 13Gs · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd.and Certain Officers – NNOXglobenewswire.com·4d agoBronstein, Gewirtz & Grossman LLC Urges Nano-X Imaging Ltd. Investors to Act: Class Action Filed Alleging Investor Harmfeeds.newsfilecorp.com·4d agoPortnoy Law Firm Announces Class Action on Behalf of Nano-X Imaging Ltd. Investorsglobenewswire.com·4d agoNNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firmprnewswire.com·4d agoCLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Nano-X Imaging (NNOX) Investors of Securities Class Action Lawsuit Deadline on August 11, 2026gurufocus.com·4d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MDT$TMDX$VREX$RCEL$STIM$BFLY$BSX$SENS
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport